Bioiogicals in the treatment of rheumatic diseases;Biologika in der therapie rheumatischer erkrankungen

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 41, 2006, Pages 2279-2285

  Scherer, Hans Ulrich ^a   Burmester, G R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biologics; Rheumatoid arthritis; Therapeutic strategies; TNF alfa antagonists; Vasculitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

CYTOTOXIC T LYMPHOCYTE; HUMAN; MONOTHERAPY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; VASCULITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CHILD; CLINICAL TRIALS, PHASE II; COHORT STUDIES; COLLAGEN DISEASES; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; METHOTREXATE; PLACEBOS; POLYMYALGIA RHEUMATICA; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; RHEUMATIC DISEASES; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; SULFASALAZINE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WEGENER GRANULOMATOSIS;

EID: 33750698593     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951364     Document Type: Review

References (64)

1. Anolik J, Campbell D, Felgar R, Rosenblatt J, Young F, Looney RJ. B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of rituximab (Rituxan®) in SLE. Arthritis Rheum 2002(Suppl46: S46
2. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 1227-1236
3. Aries PM, Lamprecht P, Gross WL. Rituximab in refractory Wegener's granulomatosis: favorable or not? Am J Respir Crit Care Med 2006; 173: 815-816
4. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-1426
5. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 7: R439-R444
6. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003; 48: 1771-1774
7. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-318
8. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285
9. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-320
10. Breedveld FC, Agarwal S, Yin M, Ng C, Li NF, Shaw T et al. Relationship between clinical response, rituximab pharmacokinetics and peripheral B cell levels in rheumatoid arthritis. Ann Rheum Dis 2006(Suppl II65: 179
11. Cohen SB, Greenwald M, Dougados MR, Emery P, Furie R, Shaw TM et al. Efficacy and Safety of Rituximab in Active R A Patients who Experienced an Inadequate Response to one or More Anti- T N F a Therapies (R E F L E X Study). American College of Rheumatology Annual Scientific Meeting 2005; Abstract #1830
12. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; (in press)
13. Edwards JC, Leandro MJ, Cambridge G. Repeated B Lymphocyte Depletion Therapy in Rheumatoid Arthritis: 5 Year Follow-Up. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #270
14. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581
15. Fleischmann RF, Racewicz JA, Schechtman J, Khraishi MM, Ferraccioli GF, Hessey E et al. Rituximab efficacy in rheumatoid arthritis is independent of coadministration of glucocorticoids: Results from the Dose-ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Study. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #263
16. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha]) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005(Suppl 464: 2-14
17. Genentech. Rituxan Prescribing Information. http://www.gene.com/gene/ products/information/immunological/rituxan/insert.jsp, 2006
18. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-1123
19. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005; 52: 548-553
20. Gladman DD. Psoriatic arthritis. Dermatol Ther 2004; 17: 350-363
21. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-3390
22. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006; 54: 678-681
23. Hoffman GS, Cid MC, Weyand CM, Stone JH, Rendt KE, Salvarani C et al. Phase II Study of the Safety and Efficacy of Infliximab in Giant Cell Arteritis (GCA):22 Week Interim Analysis. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #663
24. Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 2006; 77: 24-28
25. Kavanaugh A, Krueger GG, De Vlam K, Birbara C, Beutler A, Guzzo C et al. Infliximab Significantly Improves Joint and Skin Involvement in Psoriatic Arthritis to a Substantial Extent and Irrespective of Baseline Joint Involvement or MTX Use: Analysis of Clinical Response from the IMPACT2 Trial. American College of Rheumatology Annual Scientific Meeting 2004; Abstract#1637
26. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-187
27. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456-473
28. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-2271
29. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915
30. Landewé R, van der Heijde DM, van Vollenhoven R, Fatenejad S, Klareskog I. A Disconnect between Inflammation and Radiographic Progression in Patients Treated with Etanercept Plus Methotrexate and Etanercept Alone as Compared to Methotrexate Alone: Results from the Tempo-Trial. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #867
31. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347-356
32. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-620
33. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677
34. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-607
35. Maini RN, Taylor PC, Pavelka K, Emery P, Szechinski J, Balint G et al. Efficacy of IL-6 Receptor Antagonist MRA in Rheumatoid Arthritis Patients with an Incomplete Response to Methotrexate (CHARISMA). American College of Rheumatology Annual Scientific Meeting 2003; Abstract#1704
36. Maksymowych WP, Rahman P, Keystone E, Wong R, Inman R. Efficacy of Adalimumab in Active Ankylosing Spondylitis (AS)-Results of the Canadian AS Study. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #505
37. Märker-Hermann E, Zink A. Stellungnahme der Deutschen Gesellschaft für Rheumatologie (DGRh) zum Artikel Bongartz et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006; 295: 2275-2285 http://www.dgrh.de 2006.
38. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005(Suppl 264: ii78-ii82
39. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54: 1638-1645
40. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-3289
41. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390
42. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272
43. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004; 50: 36-42
44. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 942-945
45. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 2006; 18: 277-281
46. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-1769
47. Orencia. Orencia Prescribing Information. http://www.orencia.com/, 2006
48. Pando JA, Duray P, Yarboro C, Gourley MF, Klippel JH, Schumacher HR. Synovitis occurs in some clinically normal and asymptomatic joints in patients with early arthritis. J Rheumatol 2000; 27: 1848-1854
49. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-2749
50. Reiff A. The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 2005; 7: 434-440
51. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-670
52. Salvarani C, Manzini C, Paolazzi G, Trotta A, Manganelli P, Cimmino M et al. Infliximab in the Treatment of Polymyalgia Rheumatica: A Double Blind, Randomized, Placebo Controlled Study. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #1828
53. Sieper J, Rudwaleit M. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis 2005(Suppl 464: iv61-iv64
54. Steinfeld S, Pradier O, Song I, Burmester G, Wegener WA, Xu L et al. Epratuzumab (Anti-CD22) for the Treatment of Primary SjöGren's Syndrome. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #681
55. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 18-24
56. Van Der Kooij SM, De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, van Zeben D, Kerstens PJ, Peeters AJ et al. What treatment strategy should be chosen after initial failure on methotrexate 25 mg in early rheumatoid arthritis? Data from the BeSt Study. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #1865
57. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-2146
58. van Vollenhoven RF, Ernestam S, Cöster L, Dackhammer C, Geborek P, Hellström H et al. Methotrexate monotherapy is adequate in 30% of patients with early RA - First Report from the SWEFOT Multicenter Clinical Trial. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #1860
59. van Vollenhoven RF, Schechtman J, Szczepanski L, Fleischmann RF, Hazleman BL, Nash PT et al. Safety and Tolerability of Rituximab in Patients with Moderate to Severe Rheumatoid Arthritis: Results from the Dose-Ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) study. American College of Rheumatology Annual Scientific Meeting 2005; Abstract #1922
60. Wakefield RJ, Green MJ, Marzo-Ortega H, Conaghan PG, Gibbon WW, McGonagle D et al. Should oligoarthritis be redassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 2004; 63: 382-385
61. WGERT Study Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361
62. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7: R1281-R1288
63. Van Dongen H, Van Aken J, Lard LR, Ronday HK, Speyer I, Westedt ML, Allaart CF, Toes REM, Breedveld FC, Huizinga TWJ. Probable Rheumatoid Arthritis Methotrexate Versus Placebo Therapy (PROMPT)-Study: Indications For a Window of Opportunity In The Treatment of Patients With Undifferentiated Arthritis. Ann Rheum Dis 2006; 65 (Suppl II): 54
64. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27-35